RNA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price

$12.90

Market Cap

$1.95B

P/E (TTM)

-2.6

EPS (TTM)

$-4.97

Revenue (TTM)

$19M

Div Yield

—

ROE

-47.5%

Debt/Equity

—

52W Range

$11 – $73

RNA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income $19M

2018-12-31 → 2025-12-31

EPS $-4.97

2020-12-31 → 2025-12-31

Free Cash Flow $-664M

2020-12-31 → 2025-12-31

Margins -3650.4%

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric

5Y trend

RNA

Peer Median

P/E (TTM)

-2.6

—

P/S (TTM)

104.0

9.5

P/B

1.2

1.1

Price / FCF

-2.9

—

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric

5Y trend

RNA

Peer Median

Operating Margin

-3977.3%

—

Net Profit Margin

-3650.4%

-348.2%

ROA

-38.9%

-40.7%

ROE

-47.5%

-49.8%

ROIC

-44.2%

—

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric

5Y trend

RNA

Peer Median

Current Ratio

9.2

12.1

Quick Ratio

2.0

—

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric

5Y trend

RNA

Peer Median

Revenue YoY

72.1%

—

Revenue CAGR 3Y

26.7%

—

Revenue CAGR 5Y

22.5%

—

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric

5Y trend

RNA

Peer Median

EPS (Diluted)

$-4.97

—

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric

5Y trend

RNA

Peer Median

RNA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

BUY 7 analysts

Strong Buy 2 28.6%
Buy 4 57.1%
Hold 1 14.3%
Sell 0 0.0%
Strong Sell 0 0.0%

12-Month Price Target

4 analysts · 2026-08-19

Low $25.00

High $25.00

Median target $25.00 +93.8%

Mean target $25.00 +93.8%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise

0.09%

Period	EPS Actual	EPS Est	Surprise
March 31, 2026	$-0.97	$-1.06	0.09%

Peer comparison (GICS sub-industry) Key metrics vs sector peers

Ticker	Market Cap	P/E	Rev YoY	Net Margin	ROE	Gross Margin
RNA	$10.91B	-14.5	72.1%	-3650.4%	-47.5%	—
EBS	$644M	13.3	-28.8%	7.1%	9.9%	—
ARCT	$174M	-2.6	-46.1%	-80.2%	-29.6%	—
NBP	—	—	—	—	—	—
IMUX	—	-0.9	—	—	—	—
ORGO	$658M	34.5	17.0%	6.6%	13.9%	—
NERV	$174M	-0.1	—	—	339.5%	—
IVVD	$697M	-8.2	110.5%	-98.2%	-36.9%	—
TNXP	$200M	-1.1	29.8%	-946.2%	-60.0%	—
WHWK	$114M	-7.3	-72.5%	-288.3%	-13.4%	—
PEPG	$448M	-3.1	—	—	-82.0%	—

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Income Statement 15

Annual Income Statement data for RNA
Metric	2025	2024	2023	2022	2021	2020	2019
Revenue	$19M	$11M	$10M	$9M	$9M	$7M	$2M
R&D Expense	$559M	$304M	$191M	$150M	$101M	$38M	$15M
SG&A Expense	$206M	$86M	$54M	$38M	$26M	$13M	$5M
Operating Expenses	$765M	$390M	$245M	$188M	$127M	$51M	$20M
Operating Income	$-746M	$-379M	$-236M	$-179M	$-118M	$-44M	$-17M
Interest Expense	·	·	·	$0	$0	$209.0K	$7M
Other Non-op	$-2M	$-248.0K	$-594.0K	$-57.0K	$-62.0K	$-75.0K	$0
Pretax Income	$-685M	$-322M	$-212M	·	·	·	·
Income Tax	$0	$0	$0	$0	$0	$0	$0
Net Income	$-685M	$-322M	$-212M	$-174M	$-118M	$-44M	$-25M
EPS (Basic)	$-4.97	$-2.89	$-2.91	$-3.34	$-2.85	$-2.05	·
EPS (Diluted)	$-4.97	$-2.89	$-2.91	$-3.34	$-2.85	$-2.05	·
Shares (Basic)	137,710,000	111,582,000	73,012,000	52,162,000	41,428,000	21,663,000	·
Shares (Diluted)	137,710,000	111,582,000	73,012,000	52,162,000	41,428,000	21,663,000	·
EBITDA	$-746M	$-379M	$-236M	$-179M	$-118M	$-44M	·

Balance Sheet 24

Annual Balance Sheet data for RNA
Metric	2025	2024	2023	2022	2021	2020	2019
Cash & Equivalents	$383M	$220M	$185M	$340M	$320M	$321M	$95M
Short-term Investments	·	·	·	·	$85M	$7M	·
Receivables	·	$0	$1M	$2M	·	·	·
Prepaid Expense	$102M	$41M	$16M	$12M	$6M	·	·
Other Current Assets	$53M	$19M	·	$2M	·	·	·
Current Assets	$1.80B	$1.54B	$611M	$623M	$411M	$332M	$96M
PP&E (Net)	$23M	$13M	$8M	$6M	$5M	$1M	$631.0K
PP&E (Gross)	$35M	$21M	$14M	$9M	$7M	$3M	$2M
Accum. Depreciation	$12M	$8M	$5M	$3M	$2M	$2M	$2M
Other Non-current Assets	$82M	$521.0K	$301.0K	$598.0K	$599.0K	$47.0K	$600.0K
Total Assets	$1.96B	$1.56B	$629M	$639M	$428M	$334M	$97M
Accounts Payable	$12M	$8M	$9M	$5M	$3M	$8M	$2M
Current Liabilities	$195M	$98M	$81M	$52M	$30M	$15M	$10M
Capital Leases	$45M	$3M	$6M	$8M	$10M	$938.0K	$393.0K
Other Non-current Liabilities	·	·	·	·	·	·	$45.0K
Total Liabilities	$269M	$139M	$128M	$61M	$46M	$28M	$28M
Long-term Debt	·	·	·	·	·	·	$5M
Common Stock	$15.0K	$12.0K	$8.0K	$7.0K	$5.0K	$4.0K	$0
Paid-in Capital	·	·	·	$939M	$566M	$373M	$-43M
Retained Earnings	$-1.58B	$-893M	$-571M	$-359M	$-185M	$-67M	$-22M
AOCI	$3M	$3M	$125.0K	$-3M	$-187.0K	$-5.0K	·
Stockholders' Equity	$1.69B	$1.42B	$501M	$578M	$381M	$306M	$-65M
Liabilities + Equity	$1.96B	$1.56B	$629M	$639M	$428M	$334M	$97M
Shares Outstanding	151,205,000	119,893,000	79,275,000	69,768,000	47,754,000	37,569,000	2,989,000

Cash Flow 10

Annual Cash Flow data for RNA
Metric	2025	2024	2023	2022	2021	2020	2019
Stock-based Comp	$98M	$51M	$38M	$27M	$17M	$4M	$406.0K
Operating Cash Flow	$-650M	$-301M	$-119M	$-136M	$-95M	$-37M	$2M
CapEx	$13M	$7M	$4M	$3M	$4M	$1M	$235.0K
Investing Cash Flow	$-38M	$-854M	$-130M	$-190M	$-83M	$-8M	$-235.0K
Net Debt Issued	·	·	·	$0	$0	$-5M	·
Stock Issued	$837M	$762M	$61M	$345M	$175M	$274M	·
Net Stock Activity	$837M	$762M	$61M	$345M	$20M	·	·
Financing Cash Flow	$851M	$1.19B	$94M	$346M	$176M	$272M	$89M
Net Change in Cash	$163M	$37M	$-155M	$20M	$-1M	$227M	$91M
Free Cash Flow	$-664M	$-308M	$-123M	$-139M	$-99M	$-38M	·

Profitability 7

Annual Profitability data for RNA
Metric	2025	2024	2023	2022	2021	2020	2019
Operating Margin	-3977.3%	-3477.4%	-2464.4%	-1939.6%	-1265.8%	-652.4%	·
Net Margin	-3650.4%	-2957.7%	-2219.9%	-1886.3%	-1265.4%	-653.5%	·
Pretax Margin	-3650.4%	·	·	·	·	·	·
EBITDA Margin	-3977.3%	-3477.4%	-2464.4%	-1939.6%	-1265.8%	-652.4%	·
ROA	-38.9%	-29.4%	-33.5%	-32.6%	-31.0%	-20.6%	·
ROE	-47.5%	-22.0%	-41.7%	-36.4%	-30.4%	-14.2%	·
ROIC	-44.2%	·	·	·	·	·	·

Liquidity & Solvency 3

Annual Liquidity & Solvency data for RNA
Metric	2025	2024	2023	2022	2021	2020	2019
Current Ratio	9.2	15.7	7.6	12.0	13.9	22.7	·
Quick Ratio	2.0	2.2	2.3	6.6	13.7	22.5	·
Interest Coverage	·	·	·	·	·	-211.9	·

Efficiency 2

Annual Efficiency data for RNA
Metric	Trend	2025	2024	2023	2022	2021	2020	2019
Asset Turnover		0.0	0.0	0.0	0.0	0.0	0.0	·
Receivables Turnover		·	19.7	5.5	·	·	·	·

Per Share 5

Annual Per Share data for RNA
Metric	2025	2024	2023	2022	2021	2020	2019
Book Value / Share	$11.17	$11.89	$6.32	$8.29	$7.99	$8.15	·
Revenue / Share	$0.14	$0.10	$0.13	$0.18	·	·	·
Cash Flow / Share	$-4.72	$-2.70	$-1.63	$-2.61	·	·	·
Cash / Share	$2.53	$1.83	$2.33	$4.88	$6.71	$8.56	·
EPS (TTM)	$-4.97	$-2.89	$-2.91	$-3.34	$-2.85	$-2.05	·

Growth Rates 3

Annual Growth Rates data for RNA
Metric	2025	2024	2023	2022	2021	2020	2019
Revenue YoY	72.1%	14.0%	3.6%	-1.1%	37.4%	·	·
Revenue CAGR 3Y	26.7%	5.3%	12.1%	·	·	·	·
Revenue CAGR 5Y	22.5%	·	·	·	·	·	·

Valuation (TTM) 10

Annual Valuation (TTM) data for RNA
Metric	2025	2024	2023	2022	2021	2020	2019
Revenue TTM	$19M	$11M	$10M	$9M	$9M	$7M	·
Net Income TTM	$-685M	$-322M	$-212M	$-174M	$-118M	$-44M	·
Market Cap	$10.91B	$3.49B	$717M	$1.55B	$1.14B	$959M	·
P/E	-14.5	-10.1	-3.1	-6.6	-8.3	-12.4	·
P/S	581.5	319.9	75.0	167.8	121.7	141.3	·
P/B	6.5	2.4	1.4	2.7	3.0	3.1	·
P / Tangible Book	6.5	2.4	1.4	2.7	3.0	3.1	·
P / Cash Flow	-16.8	-11.6	-6.0	-11.4	-12.0	-25.8	·
P / FCF	-16.4	-11.3	-5.8	-11.1	-11.5	-25.1	·
Earnings Yield	-6.9%	-9.9%	-32.1%	-15.0%	-12.0%	-8.0%	·

Income Statement 12

Quarterly Income Statement data for RNA
Metric	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Revenue	$860.0K	$12M	$4M	$2M	$3M	$2M	$2M	$4M	$2M	$3M	$2M	$2M	$3M	$2M	$2M	$2M
R&D Expense	$167M	$155M	$138M	$99M	$96M	$77M	$64M	$67M	$53M	$48M	$43M	$48M	$46M	$37M	$40M	$28M
SG&A Expense	$89M	$46M	$37M	$34M	$28M	$23M	$21M	$14M	$16M	$14M	$12M	$12M	$10M	$10M	$9M	$9M
Operating Expenses	$255M	$201M	$175M	$133M	$124M	$100M	$85M	$81M	$69M	$61M	$55M	$60M	$56M	$47M	$48M	$36M
Operating Income	$-254M	$-189M	$-171M	$-132M	$-121M	$-98M	$-83M	$-77M	$-67M	$-59M	$-53M	$-58M	$-53M	$-45M	$-46M	$-34M
Other Non-op	$-477.0K	$-380.0K	$-651.0K	$-435.0K	$201.0K	$-232.0K	$-116.0K	$-101.0K	$-105.0K	$-13.0K	$-162.0K	$-314.0K	$-18.0K	$-12.0K	$-2.0K	$-25.0K
Net Income	$-237M	$-174M	$-157M	$-116M	$-102M	$-80M	$-71M	$-69M	$-60M	$-52M	$-47M	$-52M	$-50M	$-44M	$-46M	$-34M
EPS (Basic)	$-1.59	$-1.27	$-1.21	$-0.90	$-0.80	$-0.65	$-0.65	$-0.79	$-0.80	$-0.71	$-0.66	$-0.74	$-0.89	$-0.82	$-0.92	$-0.71
EPS (Diluted)	$-1.59	$-1.27	$-1.21	$-0.90	$-0.80	$-0.65	$-0.65	$-0.79	$-0.80	$-0.71	$-0.66	$-0.74	$-0.89	$-0.82	$-0.92	$-0.71
Shares (Basic)	-259,039,000	137,895,000	129,622,000	129,232,000	-205,933,000	123,375,000	106,928,000	87,212,000	-142,908,000	74,097,000	71,390,000	70,433,000	-99,080,000	53,069,000	49,927,000	48,246,000
Shares (Diluted)	-259,039,000	137,895,000	129,622,000	129,232,000	-205,933,000	123,375,000	106,928,000	87,212,000	-142,908,000	74,097,000	71,390,000	70,433,000	-99,080,000	53,069,000	49,927,000	48,246,000
EBITDA	·	$-189M	$-171M	$-132M	·	$-98M	$-83M	$-77M	·	$-59M	$-53M	$-58M	·	$-45M	·	$-34M

Balance Sheet 21

Quarterly Balance Sheet data for RNA
Metric	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Cash & Equivalents	$383M	$350M	$244M	$254M	$220M	$370M	$576M	$471M	·	$86M	$154M	$119M	·	$144M	$125M	$139M
Short-term Investments	·	·	·	·	·	·	·	·	·	·	·	·	·	$262M	$273M	$258M
Receivables	·	·	·	·	·	$0	$0	$2M	·	·	$1M	·	·	·	·	·
Prepaid Expense	$102M	$90M	$67M	$55M	$41M	$33M	$30M	$19M	·	·	$11M	·	·	·	·	·
Other Current Assets	$53M	$60M	$43M	·	$19M	·	·	·	·	·	$6M	·	·	·	·	·
Current Assets	$1.80B	$1.97B	$1.25B	$1.43B	$1.54B	$1.62B	$1.33B	$934M	·	$555M	$595M	$597M	·	$414M	$404M	$405M
PP&E (Net)	$23M	$22M	$21M	$16M	$13M	$9M	$8M	$9M	·	$8M	$8M	$8M	·	$6M	$6M	$5M
PP&E (Gross)	$35M	$32M	$30M	$24M	$21M	$17M	$15M	$15M	·	$13M	$12M	$11M	·	$9M	$9M	$7M
Accum. Depreciation	$12M	$10M	$10M	$9M	$8M	$7M	$7M	$6M	·	$5M	$4M	$4M	·	$3M	$2M	$2M
Other Non-current Assets	$82M	$91M	$91M	$739.0K	$521.0K	$318.0K	$364.0K	$425.0K	·	$344.0K	$424.0K	$474.0K	·	$523.0K	$415.0K	$548.0K
Total Assets	$1.96B	$2.13B	$1.37B	$1.46B	$1.56B	$1.64B	$1.35B	$951M	·	$573M	$611M	$614M	·	$431M	$421M	$421M
Accounts Payable	$12M	$10M	$4M	$7M	$8M	$8M	$9M	$2M	·	$6M	$6M	$4M	·	$26M	$21M	$19M
Current Liabilities	$195M	$170M	$135M	$85M	$98M	$91M	$84M	$75M	·	$49M	$45M	$48M	·	$43M	$34M	$31M
Capital Leases	$45M	$46M	$1M	$2M	$3M	$4M	$5M	$5M	·	$7M	$6M	$7M	·	$8M	$9M	$9M
Total Liabilities	$269M	$248M	$176M	$130M	$139M	$137M	$126M	$121M	·	$56M	$52M	$55M	·	$54M	$46M	$45M
Common Stock	$15.0K	$15.0K	$12.0K	$12.0K	$12.0K	$12.0K	$11.0K	$10.0K	·	$7.0K	$7.0K	$7.0K	·	$5.0K	$5.0K	$5.0K
Retained Earnings	$-1.58B	$-1.34B	$-1.17B	$-1.01B	$-893M	$-791M	$-710M	$-640M	·	$-510M	$-458M	$-411M	·	$-308M	$-264M	$-219M
AOCI	$3M	$2M	$2M	$3M	$3M	$7M	$-453.0K	$-464.0K	·	$-2M	$-3M	$-2M	·	$-3M	$-3M	$-2M
Stockholders' Equity	$1.69B	$1.89B	$1.19B	$1.33B	$1.42B	$1.50B	$1.22B	$831M	$501M	$517M	$559M	$559M	$578M	$377M	$374M	$376M
Liabilities + Equity	$1.96B	$2.13B	$1.37B	$1.46B	$1.56B	$1.64B	$1.35B	$951M	·	$573M	$611M	$614M	·	$431M	$421M	$421M
Shares Outstanding	151,205,000	146,771,000	120,778,000	120,512,000	119,893,000	118,900,000	109,266,000	95,594,000	79,275,000	74,101,000	74,070,000	70,813,000	69,768,000	54,446,000	52,081,000	49,281,000

Cash Flow 9

Quarterly Cash Flow data for RNA
Metric	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Stock-based Comp	$43M	$19M	$18M	$18M	$14M	$14M	$13M	$10M	$10M	$10M	$9M	$9M	$7M	$7M	$7M	$6M
Operating Cash Flow	$-170M	$-156M	$-200M	$-125M	$-100M	$-66M	$-65M	$-70M	$17M	$-37M	$-50M	$-49M	$-39M	$-32M	$-36M	$-30M
CapEx	$6M	$712.0K	$3M	$4M	$4M	$2M	$531.0K	$915.0K	$863.0K	$923.0K	$622.0K	$2M	$850.0K	$-107.0K	$1M	$758.0K
Investing Cash Flow	$207M	$-588M	$185M	$157M	$-64M	$-482M	$-275M	$-33M	$51M	$-31M	$46M	$-196M	$-8M	$11M	$-18M	$-175M
Stock Issued	$-538.0K	$837M	$0	$0	$-500.0K	$324M	$433M	$6M	$0	$0	$38M	$22M	$243M	$39M	$38M	$24M
Net Stock Activity	·	·	·	$0	·	·	·	$6M	·	·	·	$22M	·	·	·	$24M
Financing Cash Flow	$-5M	$850M	$4M	$2M	$14M	$342M	$447M	$389M	$32M	$40.0K	$39M	$23M	$244M	$40M	$39M	$24M
Net Change in Cash	$32M	$106M	$-10M	$34M	$-150M	$-206M	$107M	$286M	$99M	$-68M	$35M	$-222M	$197M	$19M	$-14M	$-181M
Free Cash Flow	·	·	·	$-129M	·	·	·	$-71M	·	·	·	$-51M	·	·	·	$-30M

Profitability 5

Quarterly Profitability data for RNA
Metric	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Operating Margin	·	-1513.5%	-4448.7%	-8360.9%	·	-4200.9%	-4040.4%	-2178.6%	·	-2080.4%	-2272.6%	-2579.3%	·	-1810.2%	·	-1919.8%
Net Margin	·	-1398.3%	-4089.3%	-7360.0%	·	-3441.7%	-3461.8%	-1943.4%	·	-1858.0%	-2030.4%	-2346.3%	·	-1756.6%	·	-1907.2%
EBITDA Margin	·	-1513.5%	-4448.7%	-8360.9%	·	-4200.9%	-4040.4%	-2178.6%	·	-2080.4%	-2272.6%	-2579.3%	·	-1810.2%	·	-1919.8%
ROA	·	-9.2%	-11.6%	-9.6%	·	-7.3%	-7.2%	-8.8%	·	-10.4%	-9.1%	-10.1%	·	-10.2%	·	-9.3%
ROE	·	-10.3%	-13.0%	-10.7%	·	-8.0%	-8.0%	-9.9%	·	-11.7%	-10.1%	-11.2%	·	-11.3%	·	-10.3%

Liquidity & Solvency 2

Quarterly Liquidity & Solvency data for RNA
Metric	Trend	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Current Ratio		·	11.6	9.3	16.9	·	17.8	15.8	12.5	·	11.4	13.1	12.4	·	9.7	·	13.1
Quick Ratio		·	2.1	1.8	3.0	·	4.1	6.8	6.3	·	1.8	3.4	2.5	·	9.5	·	12.8

Efficiency 2

Quarterly Efficiency data for RNA
Metric	Trend	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Asset Turnover		·	0.0	0.0	0.0	·	0.0	0.0	0.0	·	0.0	0.0	0.0	·	0.0	·	0.0
Receivables Turnover		·	·	·	·	·	·	3.5	4.5	·	·	3.9	·	·	·	·	·

Per Share 5

Quarterly Per Share data for RNA
Metric	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Book Value / Share	·	$12.85	$9.87	$11.03	·	$12.64	$11.17	$8.69	·	$6.98	$7.55	$7.89	·	$6.92	·	$7.62
Revenue / Share	·	$0.09	$0.03	$0.01	·	$0.02	$0.02	$0.04	·	$0.04	$0.03	$0.03	·	$0.05	·	·
Cash Flow / Share	·	·	·	$-0.97	·	·	·	$-0.81	·	·	·	$-0.70	·	·	·	·
Cash / Share	·	$2.39	$2.02	$2.11	·	$3.11	$5.27	$4.93	·	$1.16	$2.08	$1.68	·	$2.64	·	$2.83
EPS (TTM)	·	$-4.03	$-3.41	$-2.99	·	$-2.80	$-2.81	$-2.90	·	$-2.93	$-3.14	$-3.19	·	$-3.13	·	·

Valuation (TTM) 10

Quarterly Valuation (TTM) data for RNA
Metric	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Revenue TTM	·	$20M	$10M	$9M	·	$11M	$11M	$11M	·	$10M	$9M	$9M	·	$9M	·	$9M
Net Income TTM	·	$-528M	$-424M	$-336M	·	$-272M	$-239M	$-221M	·	$-195M	$-189M	$-176M	·	$-153M	·	$-114M
Market Cap	·	$6.39B	$3.43B	$3.56B	·	$5.46B	$4.46B	$2.44B	·	$473M	$821M	$1.09B	·	$889M	·	$910M
P/E	·	-10.8	-8.3	-9.9	·	-16.4	-14.5	-8.8	·	-2.2	-3.5	-4.8	·	-5.2	·	·
P/S	·	316.1	350.0	374.6	·	508.4	416.3	223.6	·	48.0	89.2	125.1	·	103.2	·	98.2
P/B	·	3.4	2.9	2.7	·	3.6	3.7	2.9	·	0.9	1.5	1.9	·	2.4	·	2.4
P / Tangible Book	·	3.4	2.9	2.7	·	3.6	3.7	2.9	·	0.9	1.5	1.9	·	2.4	·	2.4
P / Cash Flow	·	·	·	-28.5	·	·	·	-34.7	·	·	·	-22.2	·	·	·	-30.8
P / FCF	·	·	·	-27.7	·	·	·	-34.2	·	·	·	-21.4	·	·	·	-30.0
Earnings Yield	·	-9.2%	-12.0%	-10.1%	·	-6.1%	-6.9%	-11.4%	·	-45.9%	-28.3%	-20.8%	·	-19.2%	·	·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	$19M	$11M	$10M	$9M	$9M
Operating Margin %	-3977.3%	-3477.4%	-2464.4%	-1939.6%	-1265.8%
Net Income	$-685M	$-322M	$-212M	$-174M	$-118M
Diluted EPS	$-4.97	$-2.89	$-2.91	$-3.34	$-2.85

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Current Ratio	9.2	15.7	7.6	12.0	13.9
Quick Ratio	2.0	2.2	2.3	6.6	13.7

Cash Flow

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Free Cash Flow	$-664M	$-308M	$-123M	$-139M	$-99M

Latest News Recent headlines mentioning this company

CureVac sues Moderna for patent infringement over COVID-19 vaccines Yahoo Finance · 3 months, 3 weeks ago

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Institutional owners (13F) 20 filers · $102.7M total · As of June 30, 2026

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Institutional activity — Q2 2026 vs prior quarter

New positions	Exited positions	Increased	Decreased	Net shares change
0 (0 vs prior Q)	1 (-322 vs prior Q)	0 (0 vs prior Q)	1 (0 vs prior Q)	-8K

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution	Value	Shares	% of tracked 13F	Type
KRYGER CAPITAL Ltd	$75,398,932	1,045,320	73.42%	Shares
VANGUARD GROUP INC	$6,863,530	95,155	6.68%	Shares
EFG Asset Management (North America) Corp.	$6,499,913	149,149	6.33%	Shares
AXA Investment Managers S.A.	$4,429,239	101,658	4.31%	Shares
ANGELO GORDON & CO., L.P.	$3,245,850	45,000	3.16%	Shares
Toroso Investments, LLC	$2,628,417	36,440	2.56%	Shares
WOLVERINE TRADING, LLC	$1,023,120	24,000	1.00%	Call option
Orion Portfolio Solutions, LLC	$675,595	22,886	0.66%	Shares
CIBC WORLD MARKETS CORP	$552,372	7,658	0.54%	Shares
WOLVERINE TRADING, LLC	$456,141	10,700	0.44%	Put option
Eisler Capital Management Ltd.	$322,088	7,600	0.31%	Call option
WOLVERINE TRADING, LLC	$285,493	6,697	0.28%	Shares
Nuveen Asset Management, LLC	$167,268	5,752	0.16%	Shares
AlphaQuest LLC	$104,589	1,450	0.10%	Shares
OLIVER LAGORE VANVALIN INVESTMENT GROUP	$19,572	663	0.02%	Shares
Lindbrook Capital, LLC	$16,708	566	0.02%	Shares
COMERICA BANK	$10,956	152	0.01%	Shares
Byrne Asset Management LLC	$1,372	102	0.00%	Shares
FTB Advisors, Inc.	$511	18	0.00%	Shares
Hemington Wealth Management	$0	7	0.00%	Shares

Company insiders 20 insiders · 11 officers · 9 directors

Insider	Role	Last activity	Shares owned	Net 12m
Sarah Boyce	President and CEO	Feb. 27, 2026 D	0	$0
Michael F Maclean	Chief Financial Officer	Feb. 27, 2026 D	0	$0
Joseph Baroldi	Chief Operating Officer	Feb. 2, 2021 A	—	$0
Charles Calderaro III	Chief Technical Officer	Feb. 27, 2026 D	0	$0
Kathleen P. Gallagher	Chief Program Officer	Feb. 27, 2026 D	0	$0
Teresa Mccarthy	Chief Human Resources Officer	Feb. 27, 2026 D	0	$0
Michael W. Flanagan	Chief Scientific Officer	Feb. 27, 2026 D	0	$0
Steven George Hughes	Chief Medical Officer	Feb. 27, 2026 D	0	$0
Eric Mosbrooker	Chief Commercial Officer	Feb. 27, 2026 D	0	$0
John B Moriarty	Chief Legal Officer	Feb. 27, 2026 D	0	$0
Jae B. Kim	Chief Medical Officer	Feb. 2, 2021 A	—	$0
Simona Skerjanec	Director	Feb. 27, 2026 D	0	$0
Jean Jinsun Kim	Director	Feb. 27, 2026 D	0	$0
Tamar Thompson	Director	Feb. 27, 2026 D	0	$0
Noreen Henig	Director	Feb. 27, 2026 D	0	$0
Troy Edward Wilson	Director	Feb. 27, 2026 D	0	$0
Edward M. Kaye MD	Director	Feb. 27, 2026 D	0	$0
Carsten Boess	Director	Feb. 27, 2026 D	0	$0
LEVIN ARTHUR A	Director	Feb. 27, 2026 D	0	$0
Roderick Wong, M.D.	—	June 16, 2021 A	—	$0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

Activists & 5%+ owners 1 position

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer	Filed	Stake	Status	Purpose	Filing
RTW Investments, LP, Roderick Wong ×6 filings	Oct. 29, 2025	3.10%	Amendment	—	SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ETF ownership Held by 15 ETFs

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund	Weight	Units	As of	Source
IWC · iShares Trust	0.04%	48,184 SH	Aug. 8, 2026	Daily
OMFS · Invesco Exchange-Traded Self-Indexe…	0.02%	4,415 SH	Aug. 8, 2026	Daily
VTWO · VANGUARD SCOTTSDALE FUNDS	0.01%	82,327 SH	Aug. 8, 2026	Daily
VTWG · VANGUARD SCOTTSDALE FUNDS	0.01%	10,724 SH	Aug. 8, 2026	Daily
IWO · iShares Trust	0.01%	85,960 SH	Aug. 8, 2026	Daily
IWM · iShares Trust	0.01%	369,738 SH	Aug. 8, 2026	Daily
IWN · iShares Trust	0.00%	40,687 SH	Aug. 8, 2026	Daily
PRFZ · Invesco Exchange-Traded Fund Trust	0.00%	2,952 SH	Aug. 8, 2026	Daily
IWV · iShares Trust	0.00%	3,267 SH	Aug. 8, 2026	Daily
VXF · VANGUARD INDEX FUNDS	0.00%	188,626 SH	Aug. 8, 2026	Daily
VTI · VANGUARD INDEX FUNDS	0.00%	518,416 SH	Aug. 8, 2026	Daily
VT · VANGUARD INTERNATIONAL EQUITY INDEX…	0.00%	8,760 SH	Aug. 8, 2026	Daily
VTWV · VANGUARD SCOTTSDALE FUNDS	0.00%	3,882 SH	Aug. 8, 2026	Daily
VTHR · VANGUARD SCOTTSDALE FUNDS	0.00%	933 SH	Aug. 8, 2026	Daily
ESGV · VANGUARD WORLD FUND	0.00%	3,329 SH	Aug. 8, 2026	Daily

RNA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

RNA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

Moving averages & overlays

Volume

Oscillators

Momentum & trend

10-Year Performance Revenue, net income, margins and EPS trends

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Financial Health Debt, liquidity, solvency — balance sheet strength

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

RNA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

12-Month Price Target

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Peer comparison (GICS sub-industry) Key metrics vs sector peers

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

Latest News Recent headlines mentioning this company

My Metrics Your personal watchlist — selected rows from Full Fundamentals

Institutional owners (13F) 20 filers · $102.7M total · As of June 30, 2026

Company insiders 20 insiders · 11 officers · 9 directors

Activists & 5%+ owners 1 position

ETF ownership Held by 15 ETFs